What happened with QURE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
uniQure N.V.’s only approved product is HEMGENIX, whose exclusive worldwide commercial rights belong to CSL Behring. CSL Behring supplies all of uniQure’s revenue, predominantly through sales-based royalties, with a small contribution from development services. uniQure can also receive payments when agreed milestones are reached. It has sold part of its future HEMGENIX royalties to raise funding, so not all royalties remain available to fund its business.
Genezen manufactures HEMGENIX for CSL Behring on uniQure’s behalf. Although uniQure no longer manufactures the product itself, it remains contractually responsible for supply until manufacturing capabilities transfer to CSL Behring or its designated manufacturer.
uniQure’s development work focuses heavily on AMT-130 for Huntington’s disease, alongside other clinical-stage gene therapies for rare diseases. These candidates cannot be marketed without regulatory approval. The FDA has said AMT-130’s existing trial data compared with an external control are insufficient as primary evidence of effectiveness and has strongly recommended a randomized study with a sham-surgery control. Advancing the pipeline therefore depends on further clinical evidence and funding; uniQure has financed operations mainly through equity, debt and collaboration-partner payments.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
uniQure’s prospects hinge on AMT-130’s clinical and regulatory progress, but all reported revenue comes from HEMGENIX commercial partner CSL Behring, which is absent from this list.
Wave Life Sciences Ltd.’s RNA-based Huntington’s treatments compete with uniQure’s AMT-130 gene-silencing therapy. Watch its Huntington’s program rather than total revenue: all its 2025 revenue came from GSK, following termination of the Takeda collaboration in October 2024.
Novartis develops Huntington’s treatments that compete with uniQure’s AMT-130, making progress in that program more relevant than its broad prescription-medicine sales. Its marketed medicines span neuroscience, cancer and other diseases, with sales concentrated in the United States and Europe.
uniQure uses ClearPoint Neuro, Inc.’s neurosurgical delivery technology to administer AMT-130 directly into the brain, making ClearPoint part of the treatment’s delivery process.
Ionis Pharmaceuticals, Inc.’s RNA-targeted ALS medicines compete with uniQure’s SOD1-targeting gene therapy AMT-162. Ionis develops medicines sold both independently and through partners; Biogen handles worldwide commercialization of QALSODY, so Ionis’s total revenue is not a clean measure of this rivalry.
Sarepta Therapeutics,, Inc. is a Huntington’s competitor whose marketed AAV gene therapy also makes its safety and regulatory news relevant to uniQure. Watch ELEVIDYS: in November 2025, Sarepta announced a boxed warning for acute liver injury and acute liver failure and removal of non-ambulatory patients from its U.S. indication.
Voyager Therapeutics, Inc. and uniQure develop central nervous system gene therapies and compete in ALS, with safe, effective delivery to the brain a shared challenge. Voyager receives funding from licensing and development partners; watch its intravenously delivered TRACER therapies, whose viral carriers are designed to cross the blood-brain barrier.
Neurogene, Inc. and uniQure both use microRNA-based technologies for severe neurological diseases, making treatment safety and regulatory acceptance shared concerns. Neurogene has no product-sales revenue; watch its Phase 3 Rett syndrome program NGN-401 and its technology intended to keep gene expression within a safer range.
uniQure’s AMT-260 epilepsy program uses gene-delivery technology licensed from REGENXBIO Inc., called AAV9, with milestone payments and royalties owed under the agreement. REGENXBIO also develops its own AAV therapies, so its clinical safety and regulatory progress offer another window on the technology uniQure uses.
Xenon Pharmaceuticals Inc develops epilepsy medicines that compete with uniQure’s AMT-260 temporal lobe epilepsy program. Watch azetukalner’s Phase 3 epilepsy trials rather than sales: Xenon had no product-sales revenue in 2023–2025, and its 2025 revenue came entirely from a Neurocrine collaboration milestone.
Alnylam Pharmaceuticals, Inc. competes with uniQure in Huntington’s disease and ALS through treatments that silence genes. Alnylam also holds rights to marketed medicines and receives partner payments, so progress in its Huntington’s and ALS programs is more relevant to uniQure than its broader commercial results.
Biogen’s ALS treatments compete with uniQure’s SOD1-targeting AMT-162 development program, and Biogen handles worldwide commercialization of QALSODY. Its large multiple-sclerosis business means ALS treatment news is more relevant to this rivalry than company-wide revenue.
ClearPoint Neuro, Inc. earningsCLPT
ClearPoint Neuro’s report will show how its neurosurgical delivery business is doing, and uniQure uses its technology to deliver AMT-130 into the brain.
Look at ClearPoint Neuro’s results and commentary on its neurosurgical delivery business. Strength would support the case that this type of delivery technology is gaining broader use; weakness would offer less support, but neither outcome shows whether uniQure has the access it needs or whether AMT-130’s trial will succeed.
Biogen Inc. earningsBIIB
Biogen handles worldwide commercialization of QALSODY, so its report can show how that ALS treatment is doing in the market beyond what the company’s overall revenue reveals.
Look for Biogen’s disclosures about QALSODY sales or use, not just its total revenue. Greater use would point to stronger commercial demand and competition in ALS treatment; weak use would show limited traction for this medicine, but would not tell you how much demand AMT-162 would draw.
Xenon Pharmaceuticals Inc earningsXENE
Progress in Xenon’s Phase 3 epilepsy trials, especially for azetukalner, will show how far a competing treatment has advanced against uniQure’s AMT-260 for epilepsy patients.
Look for progress or setbacks in azetukalner’s Phase 3 trials, not Xenon’s total revenue; the company has had no product-sales revenue. Advancing trials would bring a competing treatment closer to patients; delays or problems would make that competition less immediate, but would not prove AMT-260 works or will be approved.
Sarepta Therapeutics,, Inc. earningsSRPT
Sarepta’s report may update the safety or regulatory picture for ELEVIDYS, its marketed AAV gene therapy, offering a view of the scrutiny gene therapies can face.
Look for any new regulatory change to ELEVIDYS’s liver-safety warning or who can receive it. No further restriction would mean the report shows no additional tightening of its use; tighter restrictions would show that AAV safety can carry significant regulatory consequences. ELEVIDYS is not a uniQure candidate, so its outcome does not determine how regulators will judge uniQure’s therapies.
REGENXBIO Inc. earningsRGNX
uniQure uses AAV9 technology licensed from REGENXBIO for AMT-260, and progress in REGENXBIO’s own AAV therapies offers an indirect read on that gene-delivery approach.
Look at clinical and regulatory progress in REGENXBIO’s own AAV therapies. Progress would show that AAV programs can clear development hurdles; safety or regulatory setbacks would highlight obstacles for the technology. Those are not uniQure’s AMT-260, however, so they do not directly test its licensed AAV9 or settle AMT-260’s prospects.
uniQure N.V. earningsThis company
uniQure earns most of its revenue from HEMGENIX royalties paid by CSL Behring, and this report will show whether that income is keeping pace with development spending.
Read HEMGENIX royalty revenue alongside cash used in operations. Steady or rising royalties with controlled cash use would show that this income is helping fund development; falling royalties while cash use stays high would mean uniQure is drawing down its resources faster.
Wave Life Sciences Ltd. earningsWVE
Wave’s RNA-based treatments and uniQure’s AMT-130 both target Huntington’s disease, so its report matters for program progress, not total revenue.
Look for progress or setbacks in Wave’s Huntington’s program, not total revenue; all of its 2025 revenue came from GSK. Advancement would bring another gene-silencing approach closer to patients and could intensify competition; setbacks would ease the immediate pressure, but would not prove AMT-130 works or will be approved.
